Mechanism of Action.
Retatrutide is a first-in-class triple agonist that activates three incretin and metabolic hormone receptors: GIP, GLP-1, and glucagon receptors. The GIP and GLP-1 components provide the appetite suppression, insulin sensitization, and delayed gastric emptying seen in dual agonists like tirzepatide. The addition of glucagon receptor agonism introduces a third metabolic lever: glucagon signaling increases energy expenditure, stimulates hepatic lipid oxidation, and promotes thermogenesis. This triple mechanism theoretically creates a more complete metabolic intervention by simultaneously reducing caloric intake (GLP-1/GIP), improving glucose disposal (GIP/GLP-1), and increasing energy expenditure (glucagon). The glucagon component is carefully balanced to avoid excessive hepatic glucose output.
Research Summary.
Phase 2 trial data published in the New England Journal of Medicine showed remarkable results. At the highest dose (12mg weekly), participants achieved 24.2% mean body weight loss over 48 weeks, with 26% of participants losing more than 30% of their body weight. These results exceeded both semaglutide and tirzepatide data at comparable timepoints. Eli Lilly has advanced retatrutide into Phase 3 trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The Phase 3 TRIUMPH program includes multiple large-scale trials. Early data also suggests potent effects on liver fat reduction, with near-complete resolution of hepatic steatosis in many participants.
Side Effects & Safety.
In Phase 2, gastrointestinal adverse events were common but consistent with the GLP-1 class: nausea (16-45% dose-dependent), diarrhea (15-34%), vomiting (8-23%), and constipation (6-14%). The addition of glucagon agonism raises theoretical concerns about glycemic effects, though hyperglycemia was not a significant finding in trials. Heart rate increases were observed (consistent with GLP-1 class). Long-term safety data from Phase 3 trials is pending. As an investigational compound, the full safety profile has not been established.
Legal Status & Access.
Retatrutide is an investigational drug that has not received FDA approval. It is currently in Phase 3 clinical trials conducted by Eli Lilly. It is not available through standard prescription channels. Research-grade retatrutide is available from some peptide suppliers for laboratory investigation, though quality and purity standards vary significantly for investigational compounds.